Novartis Shifts Clinical Trials to Emerging Markets, HB Reports

Novartis AG (NOVN) is shifting more of its clinical trials to emerging market regions such as Asia-Pacific, the Middle East and Africa, Handelsblatt reported, citing Novartis information.

The number of clinical trials rose to 44 percent of all of Novartis trials, not including trials of cancer drugs, the newspaper reported.

To contact the reporter on this story: Eva von Schaper in Munich at

To contact the editor responsible for this story: Phil Serafino at

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.